Development and Characterization of an Active Pharmaceutical Ingredient Using Polymeric Carriers Delivery System

¹ Department of Materials Science, Institute of Graduate Studies and Research, Alexandria University, Egypt

^*Corresponding Author

Mohamed S. Abou-Taleb

Department of Materials Science, Institute of Graduate Studies and Research,

Alexandria University,

Egypt.

Email: Mohamed.selim12@alexu.edu.eg, mselim_research@yahoo.com

Tel: +201222707520

Abstract

Cardiac diseases are the major cause of mortality, morbidity, and disability. People are dying due to cardiac problems which include atherosclerosis and myocardial infarction. Nanotechnology is the science involving the design, characterization and application of materials in at least one dimension is on nanometer scale. Angiogenesis involves primary vascular plexus formation, which involves differentiation of endothelial cells. Gene therapy makes modification of gene expression for therapeutic gain, where a"normal" gene is inserted into the genome for replacement of an "abnormal" disease-causing gene. A carrier (a vector) is used for delivery of the therapeutic gene to the target cells of patient. Gene delivery involves the ability of DNA for crossing the cell membrane, escaping from endosome, and entering the nucleus. Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen in vitro, and a potent permeability mediator and angiogenic growth factor in vivo. Poly (lactide-co-glycolide) (PLGA) is the most used polymer for pharmaceutical controlled release devices. PLGA is biodegradable and biocompatible, hydrolyzing to lactic and glycolic acid monomers. PLGA nanoparticles are potential vector for gene delivery.

Keywords: Cardiac diseases, Angiogenesis, Gene therapy, Vascular Endothelial Growth Factor, Poly-Lactide-co-Glycolide

Download the full article (PDF)